Generate Biomedicines, Inc., was incorporated under the laws of the State of Delaware in August 2018. As a clinical stage generative biology company, the company pioneered an artificial intelligence-driven biotechnology platform called Generate Platform, which combines computational models with scalable biological hardware to design and develop novel therapeutic proteins. Its most advanced drug candidate, GB-0895, is a computationally engineered anti-TSLP monoclonal antibody that is currently in a pivotal Phase 3 trial for severe asthma. The platform's capabilities have been further demonstrated by advancing two additional oncology drug candidates to Phase 1 trials in 2026.
